title: Central control of bone mass: potential therapeutic implications.
authors.affiliation: Rheumatology Department and Bone and Joint Center, Angers Teaching Hospital, 4, rue Larrey, 49 933 Angers cedex 9, France. relevasseur@chu-angers.fr
authors.forename: Régis
authors.initials: R
authors.lastname: Levasseur
authors.forename: Erick
authors.initials: E
authors.lastname: Legrand
authors.forename: Daniel
authors.initials: D
authors.lastname: Chappard
authors.forename: Maurice
authors.initials: M
authors.lastname: Audran
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects* / Q000502:physiology*; D006801:Humans; D020738:Leptin / Q000627:therapeutic use; D010024:Osteoporosis / Q000188:drug therapy; D011433:Propranolol / Q000494:pharmacology; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D020738:Leptin; D011994:Recombinant Proteins; D011433:Propranolol